Download Free Type 2 Diabetes And Dementia Book in PDF and EPUB Free Download. You can read online Type 2 Diabetes And Dementia and write the review.

Type 2 Diabetes and Dementia details the relationship between diabetes, dementia and the future of medicine and therapeutics. Chapters range from epidemiology, clinical features, neuroimaging biomarkers, neuropathology, macrostructural and molecular mechanisms, risk assessment and prevention strategies, and the application of therapeutics. The book reflects the translational aspects of the current science in the field, with an emphasis on the display of neuroimaging and neuropathology. It contains contributions from world experts, and is ideal for clinicians and researchers in the fields of neurology, neuroscience, geriatric medicine and endocrinology. - Presents a comprehensive overview that details the relationship between diabetes, dementia and the future of medicine and therapeutics - Written for researchers and clinicians in neurology, neuroscience, geriatric medicine and endocrinology - Includes topics ranging from epidemiology, clinical features, neuroimaging biomarkers, neuropathology, macrostructural and molecular mechanisms, risk assessment, prevention strategies and therapeutic applications
The editor of this volume, having research interests in the field of ROS production and the damage to cellular systems, has identified a number of enzymes showing ·OH scavenging activities details of which are anticipated to be published in the near future as confirmatory experiments are awaited. It is hoped that the information presented in this book on NDs will stimulate both expert and novice researchers in the field with excellent overviews of the current status of research and pointers to future research goals. Clinicians, nurses as well as families and caregivers should also benefit from the material presented in handling and treating their specialised cases. Also the insights gained should be valuable for further understanding of the diseases at molecular levels and should lead to development of new biomarkers, novel diagnostic tools and more effective therapeutic drugs to treat the clinical problems raised by these devastating diseases.
The thought of living out one's life with dementia conjures up a helpless and foreboding feeling. What if it happens to me?Can I do anything to prevent it?One in ten people age 65 and older has Alzheimer's, and the prevalence of the disease jumps to three in ten after the age of 85. One in three seniors will die from Alzheimer's or another form of dementia according to the Alzheimer's Association. The financial burden for top level care can be staggering, and the difficult challenges imposed by attending to care and finances can be extremely stressful and exhausting for family as well as caretakers.Is there an answer for you and the Alzheimer's pandemic that is projected to almost triple by the year 2050? To date, drug trials are struggling to provide any meaningful interventions, and it is unlikely that a pharmaceutical centered approach will provide anything resembling a cure or a reversal of the disease process anytime soon. There is hope! The solution is based on early detection and intervention. Scientific research as well as many enlightened physicians and clinics are now demonstrating that prevention is possible, and the key lies in a comprehensive evaluation of your risk for Alzheimer's long before the onset of dementia. This is vital as we now know that the Alzheimer's disease process starts decades before you might notice you are in trouble.Don't wait to be diagnosed! The Diabetic Brain in Alzheimer's Disease reveals the most critical and common risk factors for Alzheimer's disease as you age, and how you can take control of your risk. The in-depth science-based information in this book will illuminate your path to protecting your brain and drastically reducing your odds of developing Alzheimer's as you age. Read this book and discover the actionable steps that you can begin taking now to save your brain from dementia.
Neurodegenerative diseases represent a very large group of heterogeneous disorders affecting specific subtypes of neurons in the brain. This book contributes insight both to the awareness of the brain and its neurodegenerative states. The chapters present current knowledge regarding genetics, molecular mechanisms, and new therapeutic strategies against neurodegenerative disorders. The book is intended to serve as a source to aid clinicians and researchers in the field, and also life science readers to increase their understanding and awareness of the clinical correlations, genetic aspects, neuropathological findings, and current therapeutic interventions in neurodegenerative diseases. I believe that this book will enlighten the curiosity for neurodegeneration and also encourage researchers to work on potentially effective molecular therapies for still mysterious neurodegenerative disorders.
Societies around the world are concerned about dementia and the other forms of cognitive impairment that affect many older adults. We now know that brain changes typically begin years before people show symptoms, which suggests a window of opportunity to prevent or delay the onset of these conditions. Emerging evidence that the prevalence of dementia is declining in high-income countries offers hope that public health interventions will be effective in preventing or delaying cognitive impairments. Until recently, the research and clinical communities have focused primarily on understanding and treating these conditions after they have developed. Thus, the evidence base on how to prevent or delay these conditions has been limited at best, despite the many claims of success made in popular media and advertising. Today, however, a growing body of prevention research is emerging. Preventing Cognitive Decline and Dementia: A Way Forward assesses the current state of knowledge on interventions to prevent cognitive decline and dementia, and informs future research in this area. This report provides recommendations of appropriate content for inclusion in public health messages from the National Institute on Aging.
Thiamine Deficiency Disease, Dysautonomia, and High Calorie Malnutrition explores thiamine and how its deficiency affects the functions of the brainstem and autonomic nervous system by way of metabolic changes at the level of the mitochondria. Thiamine deficiency derails mitochondrial oxidative metabolism and gives rise to the classic disease of beriberi that, in its early stages, can be considered the prototype for a set of disorders that we now recognize as dysautonomia. This book represents the life's work of the senior author, Dr. Derrick Lonsdale, and a recent collaboration with his co-author Dr. Chandler Marrs. - Presents clinical experience and animal research that have answered questions about thiamine chemistry - Demonstrates that the consumption of empty calories can result in clinical effects that lead to misdiagnosis - Addresses the biochemical changes induced by vitamin deficiency, particularly that of thiamine
There is now considerable genetic evidence that the type 4 allele of the apolipoprotein E gene is a major susceptibility factor associated with late-onset Alzheimer's disease, the common form of the disease defined as starting after sixty years of age. The role of apolipoprotein E in normal brain metabolism and in the pathogenesis of Alzheimer's disease are new and exciting avenues of research. This book, written by the most outstanding scientists in this new filed, is the first presentation of results concerning the implications of apolipoprotein E on the genetics, cell biology, neuropathology, biochemistry, and therapeutic management of Alzheimer's disease.
Endocrinology and metabolic diseases are an important area of study in any medical course. This fully indexed text covers the essentials of the subject in a succint and lucid fashion, and several hundred illustrations with numbered labels allow for quick revision.
Dementia, technically defined as cognitive impairments sufficiently pervasive and severe enough that they disrupt independent life, is one of the most devastating symptoms of neurologic disease. While Alzheimer's disease (AD) is the most common neurodegenerative disease that causes it, more than 50 medical, psychiatric, and neurological conditions are associated with dementia. Well organized and expertly planned, this text provides new concepts of patient management that have come about through recent neuroscience research. This volume, reviewing the dementias with the needs of the clinician in mind, is unique in that the section dealing with disease mechanisms reviews the exciting recent scientific advance in regard to Alzheimer disease, whereas the clinical section(section A) focuses not on Alzheimer disease but upon related disorders, the less common dementing syndromes due to other neurodegenerative disorders. The editors of this Blue Book have brought together an extraordinary group of experts to define the scientific advances primarily in Alzheimer's disease (section B) and new treatments (section C) being developed. * Written for non-expert general neurologists and residents * Provides new concepts of patient management discovered in neuroscience research * Includes unique coverage of recent scientific advances in Alzheimer's Disease
"Dementia, diabetes, and hypertension are considered huge medical problems around the world, costing many millions of dollars to the medical health systems. Curiously, hypertension has been clinically linked with a higher risk for decline of cognition, as shown in dementia patients. In addition, there is a clear clinical association between hypertension and diabetes, reflecting substantial similarities in their etiology. In fact, consistent data support that patients diagnosed with diabetes have shown an increased risk of presenting cognitive dysfunctions, clinical signs of dementia. Considering the cumulative knowledge from the scientific literature, we can now link Ca2+ signals dysregulations as an upstream issue for hypertension, diabetes and other inflammatory processes, and dementia. Regarding therapeutics, hypertensive patients have been classically treated with Ca2+ channel blockers (CCBs), medicines whose mechanism of action consists in reducing the influx of Ca2+ into the cells. Intriguingly, many clinical reports have been demonstrating off-label effects for CCBs. In hypertensive patients treated with CCBs, it can be observed a lower incidence of dementia such as Alzheimer's disease. The possible mechanism of action could be attributed to a restoration of the Ca2+ homeostasis. In addition, in hypertensive patients treated with CCBs, it can be also observed an improvement of diabetes status such as glycemic control. A possible mechanism of action could be due to a restoration of insulin secretion, then achieving glycemic control, and a reduction of the pancreatic [beta]-cell apoptosis. Thus, this book puts together fundamental concepts, and current therapies to treat dementia, hypertension, and diabetes, including novel therapeutics coming from the pharmacological manipulation of Ca2+/cAMP signalling. Finally, this book compiles more than 300 references from the scientific literature, including data of high evidence such as meta-analysis and systematic reviews, and discusses pharmaceuticals already approved and clinically safe, e.g., CCBs, then allowing sustained increments in the life quality of age-related patients"--